Nektar Technology is a music technology company that designs and manufactures innovative MIDI controllers, keyboard controllers, and software for music production and performance.

Nektar Technology, Inc.

Vistex, Inc provides revenue management solutions and services to help businesses optimize their financial operations and maximize profitability.

Vistex, Inc

Nektar Therapeutics is a research-based development stage biopharmaceutical company that discovers and develops innovative medicines in areas of high unmet medical need. Our R&D pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and viral diseases. We leverage Nektar's proprietary and proven chemistry platform in the discovery and design of our new drug candidates.

Pearl Therapeutics

Deerfield

SFJ Pharmaceuticals

AstraZeneca

New Enterprise Associates

Nektar Therapeutics

At #JPM2024 next week, Nektar’s management team will present on exciting company updates across our #immunology and #immunooncology pipelines. Learn more about us: https://bit.ly/47nZHVe

New preclinical data presented at #ASH23 by our collaborators at NYMC highlight that NKTR-255, in combination with obinutuzumab, expanded NK cells and enhanced antibody-dependent cellular cytotoxicity against rituximab-resistant Burkitt lymphoma cells. Learn more: https://bit.ly/48fE3DO

We’re celebrating Mary Tagliaferri, MD, Nektar’s Chief Medical Officer, who was recently named as one of Inc. Magazine’s 10 Most Eminent Women Leaders in Healthcare 2023. Learn more about Mary and the vital role she plays at Nektar directing clinical strategy, operations and medical affairs: https://bit.ly/3smei5l

At #EADVCongress this week, we presented new and encouraging responder data in late-breaking news oral presentation for Rezpegaldesleukin, our first-in-class selective T-reg therapy, in patients with #atopicdermatitis, also being studied in #alopeciaareata. Full press release: https://bit.ly/3M1sIye

We’re gearing up for #EADVCongress next week, where Nektar will have two presentations for Rezpegaldesleukin, our first-in-class selective regulatory T-cell therapy, being studied in #atopicdermatitis and #alopeciaareata. Additional details: https://bit.ly/3ZDSoXx

Metric
Company Name	Nektar Technology, Inc.	Vistex, Inc
Symbol
MSH ID	COM:NEKTARTECH	COM:VISTEX
Market	PRIVATE	PRIVATE
Sector	Technology	Financial Services & Finance
Industry	Music Technology	Revenue Management Solutions
Country		US
Stage		Corporate Round
Employee Count
Website	nektar.com	vistex.com
LinkedIn		vistex
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic		95.88K
Web Traffic Growth		1.69
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:NEKTARTECH

Nektar Therapeutics

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue